Raphael Pharmaceutical Stock Cash Per Share
| RAPH Stock | 0.26 0.00 0.00% |
Raphael Pharmaceutical fundamentals help investors to digest information that contributes to Raphael Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Raphael OTC Stock. The fundamental analysis module provides a way to measure Raphael Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Raphael Pharmaceutical otc stock.
Raphael |
Raphael Pharmaceutical OTC Stock Cash Per Share Analysis
Raphael Pharmaceutical's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Raphael Pharmaceutical has a Cash Per Share of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Cash Per Share (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Raphael Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Raphael Pharmaceutical's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Raphael Pharmaceutical could also be used in its relative valuation, which is a method of valuing Raphael Pharmaceutical by comparing valuation metrics of similar companies.Raphael Pharmaceutical is currently under evaluation in cash per share category among its peers.
Raphael Fundamentals
| Return On Asset | -19.04 | |||
| Shares Outstanding | 15.62 M | |||
| EBITDA | (1.63 B) | |||
| Net Income | (1.62 B) | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.42 M) | |||
| Market Capitalization | 17.19 M | |||
| Total Asset | 422 K | |||
| Net Asset | 422 K |
About Raphael Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Raphael Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Raphael Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Raphael Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.